MX355461B - Una formulacion estabilizada de pemetrexed. - Google Patents

Una formulacion estabilizada de pemetrexed.

Info

Publication number
MX355461B
MX355461B MX2015006325A MX2015006325A MX355461B MX 355461 B MX355461 B MX 355461B MX 2015006325 A MX2015006325 A MX 2015006325A MX 2015006325 A MX2015006325 A MX 2015006325A MX 355461 B MX355461 B MX 355461B
Authority
MX
Mexico
Prior art keywords
pemetrexed formulation
stabilized pemetrexed
stabilized
formulation
acetylcysteine
Prior art date
Application number
MX2015006325A
Other languages
English (en)
Other versions
MX2015006325A (es
Inventor
Young Joon Park
Myung Jin Shin
Hong Chul Jin
Ha Yong Choi
Nak Hyun Choi
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48665454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX355461(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of MX2015006325A publication Critical patent/MX2015006325A/es
Publication of MX355461B publication Critical patent/MX355461B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)

Abstract

La presente invención se refiere a una formulación estabilizada de pemetrexed y más en particular, a una formulación estabilizada de pemetrexed que comprende acetilcisteína como antioxidante y una sal de citrato como tampón.
MX2015006325A 2012-11-29 2013-11-29 Una formulacion estabilizada de pemetrexed. MX355461B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120137375A KR101260636B1 (ko) 2012-11-29 2012-11-29 안정화된 페메트렉시드 제제
PCT/KR2013/010967 WO2014084651A1 (en) 2012-11-29 2013-11-29 A stabilized pemetrexed formulation

Publications (2)

Publication Number Publication Date
MX2015006325A MX2015006325A (es) 2016-02-25
MX355461B true MX355461B (es) 2018-04-19

Family

ID=48665454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006325A MX355461B (es) 2012-11-29 2013-11-29 Una formulacion estabilizada de pemetrexed.

Country Status (16)

Country Link
US (1) US9265832B2 (es)
EP (1) EP2925325B1 (es)
JP (1) JP5934448B2 (es)
KR (1) KR101260636B1 (es)
CN (1) CN104812392B (es)
AR (1) AR093645A1 (es)
BR (1) BR112015012460B1 (es)
CL (1) CL2015001461A1 (es)
ES (1) ES2656901T3 (es)
HK (1) HK1212224A1 (es)
JO (1) JOP20130342B1 (es)
MX (1) MX355461B (es)
PH (1) PH12015500900B1 (es)
RU (1) RU2620341C2 (es)
TW (1) TWI498128B (es)
WO (1) WO2014084651A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
EP3040074B1 (en) * 2013-10-03 2018-07-25 Fujifilm Corporation Injection preparation and method for producing same
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
EP3124026B1 (en) * 2014-03-28 2018-07-25 Fujifilm Corporation Injection preparation and method for producing same
GB201418555D0 (en) * 2014-10-16 2014-12-03 Teva Gmbh Pemetrexed formulations
KR101770605B1 (ko) 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
WO2019043569A1 (en) * 2017-08-29 2019-03-07 Fresenius Kabi Oncology Limited STREAMABLE LIQUID COMPOSITIONS OF PEMETREXED
KR102040034B1 (ko) 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
US10966982B2 (en) 2018-11-20 2021-04-06 Cipla Limited Stable pharmaceutical formulations of pemetrexed
US20230201203A1 (en) * 2020-04-09 2023-06-29 Emphascience, Inc. Methods of treatment using antifolates and pharmaceutical formulations comprising antifolates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
DK1265612T3 (da) * 2000-02-04 2004-08-09 Lilly Co Eli Farmaceutisk præparat omfattende pemetrexed samt monothioglycerol, l-cystein eller thioglycolsyre
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
ES2336034T3 (es) 2004-03-10 2010-04-07 Shimoda Biotech (Pty) Ltd Composiciones de diclofenaco inyectables estables.
DE602007011384D1 (de) * 2006-08-14 2011-02-03 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure
US20090181990A1 (en) * 2007-12-23 2009-07-16 Patel Nileshkumar S Stable amorphous form of pemetrexed disodium
JP2013540104A (ja) 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
KR101260636B1 (ko) 2013-05-13
TWI498128B (zh) 2015-09-01
BR112015012460B1 (pt) 2022-04-05
WO2014084651A1 (en) 2014-06-05
JP5934448B2 (ja) 2016-06-15
US20150297724A1 (en) 2015-10-22
HK1212224A1 (en) 2016-06-10
RU2620341C2 (ru) 2017-05-24
PH12015500900A1 (en) 2015-07-06
EP2925325B1 (en) 2017-11-01
CN104812392A (zh) 2015-07-29
BR112015012460A2 (es) 2017-08-22
CL2015001461A1 (es) 2015-10-23
TW201434493A (zh) 2014-09-16
EP2925325A4 (en) 2016-07-13
US9265832B2 (en) 2016-02-23
PH12015500900B1 (en) 2015-07-06
AR093645A1 (es) 2015-06-17
JOP20130342B1 (ar) 2021-08-17
ES2656901T3 (es) 2018-02-28
JP2016500099A (ja) 2016-01-07
EP2925325A1 (en) 2015-10-07
MX2015006325A (es) 2016-02-25
CN104812392B (zh) 2017-05-17
RU2015122023A (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12016500586A1 (en) Stabilized efinaconazole compositions
IL234014A0 (en) Cycloalkane derivatives, preparations containing them and their uses
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX361499B (es) Baricitinib deuterado.
SG11201506149SA (en) Polyetheramines based on 1,3-dialcohols
PL2984076T3 (pl) Estry i etery 2,5-tetrahydrofuranu jako plastyfikatory
CA2875305C (en) Fbxo3 inhibitors
IL242195B (en) Dicarboxylic acid compounds, compositions comprising same and uses thereof
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
HK1207317A1 (en) Substituted 1,6-naphthyridines 16-
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
MY175703A (en) Tablets with improved acceptance and good storage stability
EP2892511A4 (en) BOLAAMPHIPHILE COMPOUNDS, COMPOSITIONS AND USES THEREOF
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
MX2015005510A (es) Forma salina solida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IL237541A0 (en) Amphiphilic compounds, their preparations and uses
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
UA80812U (en) ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE
UA86158U (en) Antibacterial agent
IN2013CH00453A (es)
AU2012904225A0 (en) 28.8Scanfit
AU2012901213A0 (en) 28.8trackside

Legal Events

Date Code Title Description
FG Grant or registration